These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 8416715)
1. Type II estrogen binding sites and antiproliferative activity of quercetin in human meningiomas. Piantelli M; Rinelli A; Macrì E; Maggiano N; Larocca LM; Scerrati M; Roselli R; Iacoangeli M; Scambia G; Capelli A Cancer; 1993 Jan; 71(1):193-8. PubMed ID: 8416715 [TBL] [Abstract][Full Text] [Related]
2. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Caltagirone S; Ranelletti FO; Rinelli A; Maggiano N; Colasante A; Musiani P; Aiello FB; Piantelli M Am J Respir Cell Mol Biol; 1997 Jul; 17(1):51-9. PubMed ID: 9224209 [TBL] [Abstract][Full Text] [Related]
3. Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy. Schrell UM; Adams EF; Fahlbusch R; Greb R; Jirikowski G; Prior R; Ramalho-Ortigao FJ J Neurosurg; 1990 Nov; 73(5):743-9. PubMed ID: 2213164 [TBL] [Abstract][Full Text] [Related]
4. Growth-inhibitory effect of quercetin and presence of type II estrogen binding sites in primary human transitional cell carcinomas. Larocca LM; Giustacchini M; Maggiano N; Ranelletti FO; Piantelli M; Alcini E; Capelli A J Urol; 1994 Sep; 152(3):1029-33. PubMed ID: 8051728 [TBL] [Abstract][Full Text] [Related]
5. Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids. Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; Rumi C; Battaglia F; Larocca LM; Capelli A; Mancuso S Int J Cancer; 1990 Dec; 46(6):1112-6. PubMed ID: 2249899 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. Scambia G; Ranelletti FO; Panici PB; Piantelli M; Bonanno G; De Vincenzo R; Ferrandina G; Rumi C; Larocca LM; Mancuso S Br J Cancer; 1990 Dec; 62(6):942-6. PubMed ID: 2257224 [TBL] [Abstract][Full Text] [Related]
7. [Immunohistopathological analysis of estrogen receptors in human meningioma]. Sawada T; Oinuma T; Saitoh M; Shinbashi M; Nishino H; Sakurai I Rinsho Byori; 1993 Jun; 41(6):698-702. PubMed ID: 8361037 [TBL] [Abstract][Full Text] [Related]
8. Meningiomas and hormonal receptors. Immunohistochemical study in typical and non-typical tumors. Hilbig A; Barbosa-Coutinho LM Arq Neuropsiquiatr; 1998 Jun; 56(2):193-9. PubMed ID: 9698727 [TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation. Bozzetti C; Camisa R; Nizzoli R; Manotti L; Guazzi A; Naldi N; Mazza S; Nizzoli V; Cocconi G Surg Neurol; 1995 Mar; 43(3):230-3; discussion 234. PubMed ID: 7792684 [TBL] [Abstract][Full Text] [Related]
10. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features. Markwalder TM; Zava DT; Goldhirsch A; Markwalder RV Surg Neurol; 1983 Jul; 20(1):42-7. PubMed ID: 6867927 [TBL] [Abstract][Full Text] [Related]
11. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations]. Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872 [TBL] [Abstract][Full Text] [Related]
12. Presence of progesterone receptors and absence of oestrogen receptors in human intracranial meningioma cytosols. Blankenstein MA; Blaauw G; Lamberts SW; Mulder E Eur J Cancer Clin Oncol; 1983 Mar; 19(3):365-70. PubMed ID: 6683174 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous estradiol and progesterone receptor analysis in meningiomas. Lesch KP; Fahlbusch R Surg Neurol; 1986 Sep; 26(3):257-63. PubMed ID: 3738720 [TBL] [Abstract][Full Text] [Related]
15. Progesterone and estrogen receptors in meningiomas: prognostic considerations. Hsu DW; Efird JT; Hedley-Whyte ET J Neurosurg; 1997 Jan; 86(1):113-20. PubMed ID: 8988089 [TBL] [Abstract][Full Text] [Related]
16. Specific estradiol binding in schwannomas, meningiomas, and neurofibromas. Martuza RL; MacLaughlin DT; Ojemann RG Neurosurgery; 1981 Dec; 9(6):665-71. PubMed ID: 7198726 [TBL] [Abstract][Full Text] [Related]
17. Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids. Larocca LM; Piantelli M; Leone G; Sica S; Teofili L; Panici PB; Scambia G; Mancuso S; Capelli A; Ranelletti FO Br J Haematol; 1990 Aug; 75(4):489-95. PubMed ID: 2207000 [TBL] [Abstract][Full Text] [Related]
18. Growth-inhibitory effect of tamoxifen and quercetin and presence of type II estrogen binding sites in human laryngeal cancer cell lines and primary laryngeal tumors. Ferrandina G; Almadori G; Maggiano N; Lanza P; Ferlini C; Cattani P; Piantelli M; Scambia G; Ranelletti FO Int J Cancer; 1998 Aug; 77(5):747-54. PubMed ID: 9688309 [TBL] [Abstract][Full Text] [Related]
19. Interaction of tamoxifen with cytosolic and nuclear type II estrogen binding sites (type II EBS). Ferrandina G; Ranelletti FO; Scambia G; Benedetti Panici P; D'Agostino G; Piantelli M; Isola G; Mancuso S Cancer Lett; 1995 Sep; 96(1):123-31. PubMed ID: 7553600 [TBL] [Abstract][Full Text] [Related]
20. Correlations of female steroid hormone receptors with histologic features in meningiomas. Piquer J; Cerda M; Lluch A; Barcia Salorio JL; Garcia-Conde J Acta Neurochir (Wien); 1991; 110(1-2):38-43. PubMed ID: 1882717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]